First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 …
…, M Aglietta, P García-Alfonso… - Journal of Clinical …, 2022 - ingentaconnect.com
PURPOSE Nivolumab received US Food and Drug Administration approval as a single
agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch …
agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch …
[HTML][HTML] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
…, TK Guren, HT Arkenau, P Garcia-Alfonso… - … England Journal of …, 2019 - Mass Medical Soc
Background Patients with metastatic colorectal cancer with the BRAF V600E mutation have
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy…
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy…
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line …
…, A Grothey, J Prausová, P Garcia-Alfonso… - The Lancet …, 2015 - thelancet.com
Background Angiogenesis is an important therapeutic target in colorectal carcinoma.
Ramucirumab is a human IgG-1 monoclonal antibody that targets the extracellular domain of VEGF …
Ramucirumab is a human IgG-1 monoclonal antibody that targets the extracellular domain of VEGF …
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label …
Background Patients with advanced gastric or gastro-oesophageal junction cancer that
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel …
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel …
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind …
CS Fuchs, K Shitara, M Di Bartolomeo… - The Lancet …, 2019 - thelancet.com
Background VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis
can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess …
can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess …
[HTML][HTML] Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E–mutant metastatic colorectal cancer: updated survival results and …
…, TK Guren, HT Arkenau, P Garcia-Alfonso… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib
versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with …
versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with …
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
…, E Elez, T Yoshino, A Sobrero, J Yao, P García-Alfonso… - The Lancet, 2023 - thelancet.com
Background There is a paucity of effective systemic therapy options for patients with advanced,
chemotherapy-refractory colorectal cancer. We aimed to evaluate the efficacy and safety …
chemotherapy-refractory colorectal cancer. We aimed to evaluate the efficacy and safety …
Oral drugs in the treatment of metastatic colorectal cancer
P García-Alfonso, AJ Muñoz Martín… - Therapeutic …, 2021 - journals.sagepub.com
Colorectal cancer (CRC) is one of the most common forms of cancer, with an estimated 1.36
million new cases and almost 700,000 deaths annually. Approximately 21% of patients with …
million new cases and almost 700,000 deaths annually. Approximately 21% of patients with …
[HTML][HTML] Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping …
P García-Alfonso, M Saiz-Rodríguez… - Clinical and …, 2022 - Springer
5-Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in
the treatment of cancer, especially gastrointestinal tumors and breast cancer, but their …
the treatment of cancer, especially gastrointestinal tumors and breast cancer, but their …
[HTML][HTML] Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic …
…, R García-Carbonero, T Ciuleanu, P García-Alfonso… - Annals of …, 2019 - Elsevier
Background Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS)
versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard …
versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard …